DeepCyte, a techbio company using AI and single-cell biology to identify and explain drug toxicity, has launched with $1.5 million in seed funding. Co-founded by Theodore Alexandrov, Ph.D., and Shawn Owens, the company is building tools that tell biopharma teams not just whether a drug causes harm, but which cells it affects and why. It










